Key facts
- CRISPR QC’s last known valuation is $25.0M (Apr 2025).
- It has raised $11.6M.
- Notable investors include MedTech Innovator, Keiretsu Forum, CONNECT (San Diego), Serra Ventures, BioTools Innovator — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for CRISPR QC
- ·The full record, as it builds
Funding rounds
No funding rounds for CRISPR QC are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CRISPR QC
Developer of an analytics platform designed to simulate the gene editing process before introduction to cells. The company's platform provides key cornerstones of information and insight fundamental to realizing the full potential and quality control for clustered regularly interspaced short palindromic repeats gene editing, enabling scientists to increase editing efficiency and define a strategy to achieve better outcomes at the cellular level.
- Sector
- Healthcare
- HQ
- San Diego, CA, United States
- Founded
- 2021
- Employees
- 12
- Website
- crisprqc.com/
- Ownership
- Privately Held (backing)
CRISPR QC doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CRISPR QC shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CRISPR QC in its N-PORT filings yet. We sweep new filings monthly.